PharmaTimes - April 2020

As the impact of the global COVID-19 pandemic hits hard and fast, PharmaTimes is open for business as usual and our team remains steadfast in its aim to seek out and deliver high-quality, credible news relevant to pharma and healthcare. Stay abreast with all the latest developments across these sectors by signing up to receive our daily news alert at www.pharmatimes.com/ subscribe

This month’s issue of PharmaTimes Magazine begins with John Pinching’s comment on the UK’s handling of COVID-19, while on page 14 there’s also a special report from Ana Nicholls on the potential impact of the virus on the economy and healthcare spend.

Elsewhere, on page 20 Hilary Thomas considers the progress and challenges in reaping the benefits of genomics, while Lev Gerlovin and Pascale Diesel (p22) look at how cell and gene therapies are driving new deals in life sciences.

We also revisit the ongoing review of NICE methods and processes (p25), with Nicola Boyd asking whether the consultation will pave the way the way for health technology assessment reform.

Finally, PharmaTimes is thrilled to announce the launch of Marketer of the Year, the Sales Awards and Communications Team of the Year Awards, which are now all open for entry. Also, tickets are on sale for the International Clinical Researcher of the Year 2020 Gala dinner, which will now take place on October 2. Please visit www.pharmatimes.com/ competitions for more information.

I hope you enjoy the issue!

April 2020 - magazine highlights

Patient Files: Osteogenesis imperfecta

Ingunn Westerheim shares her experiences of life with a ra...

Smart People: Stephen Nabarro

Stephen Nabarro, head of clinical operations and data mana...

A changing landscape

Gustaf Duhs considers the legal issues surrounding the rap...

Transformational change

The decade ahead for UK pharma – a shot in the arm or bitt...

Pitch perfect

A perfect pitch process benefits pharma as much as the age...

A NICE transformation?

Will the NICE Review of Methods and Processes pave the way...

Unlocking value

How cell and gene therapies are driving new deals in life...

On track?

Is the NHS Long Term Plan still on track? Oli Hudson and P...

Driving value from genomics

Hilary Thomas considers the progress and challenges in rea...